FOLH1 and metastatic neoplasm: The capacity to perform highly sensitive molecular imaging of PSMA to detect minute foci of metastatic disease, led by PET-isotope labeled, PSMA-targeted small molecules, is motivating a paradigm shift in prostate cancer patient management.